Press release

First patient included in Theraclion’s « Forfait Innovation » study

Theraclion announces a major milestone in its efforts to enter into the varicose veins market: the last patient of the CE marking study has been treated.

Theraclion announces today significant milestones in sales and business development in the German market.

First oncological veterinary patient now cancer free after treatment with Theraclion’s Echopulse

First Echopulse® system sale recorded for use in the French “Forfait Innovation”

First podium presentation at International Vein Congress for Theraclions’ Echopulse for varicose veins

Theraclion accelerates its sales and clinical development in Asia

Theraclion sells first Echopulse system to Catalonia, Spain

Theraclion Accelerates its Growth in 2017

Theraclion nominates a new Non-Executive Director: Mr Renaud Saleur